In Vivo models for oncology study

Oncodesign can help you select the appropriate in vivo model for your research program

Since 1995, Oncodesign has been developing models to study and treat cancer. Our extensive knowledge covers a wide in vivo pharmacological scope from syngeneic to xenograft including humanized models.
If the perfect model is not available, we can develop a custom one with you.


At Oncodesign

Location of tumor

Species information

More details

Descriptive scheme of syngeneic model


Descriptive scheme of CDX model

Cell-line-derived xenograft (CDX)

Descriptive scheme of PDX model

Patient-derived xenograft (PDX)


In combination with our medicinal chemists, in vitro biologists and pharmacologists, our integrated team can expedite your research program. Learn more about our integrated services:

  • INPACT: integrated service in preclinical pharmacology
  • DRIVE-IDDS: integrated drug discovery solutions to generate novel drug candidates

Let’s talk about your project


Let’s explore our in vivo models in the following case studies

Disease efficacy models of cancer immunotherapy combined with radiotherapy in syngeneic mice

In this example, mice were subcutaneously (SC) injected with CT-26 murine colon tumor cells on day 0. Mice were randomized based on tumor volume on day 12 and treated with imaged guide 3D radiotherapy at 8Gy for three consecutive days. T/C % (day 21) indicates the efficacy of radiotherapy.​

Moreover, combined-modality approaches with immunotherapy may increase the curative capacity of radiation therapy.

Oncodesign has developed several models for such combined-modality approaches (CT-26, 4T1, EMT6, B6-F10, RenCa, etc.).


Legend: Tumor localized radiotherapy on mice with CT-26 murine colon tumor cells.

PDX models: Single Mouse Preclinical Trial (SMPT) for in vivo profiling and drug combination optimization

In this SMPT study including 27 colon PDXs, tumor models were treated with standard of care (SoC) alone (5-FU or Oxaliplatin) and FOLFOX (5-FU, Oxaliplatin, folinic acid).


Legend: SMPT study including 27 colon PDXs

FOLFOX increased the tumor response when compared to each mono therapies (in colon PDX models). Combination therapy increased the tumor response when compared to each mono therapies (in colon PDX models)


Oncodesign is continually building a collection of well characterized models. We currently have more than 500 models covering 35 cancer pathologies.

Let’s talk about your project to see which model would best suit your research program.


Chi-Mice® case study – Immune checkpoint inhibitor in humanized model

NOG (NOD/Shi-scid/IL-2Rγnull) mice were injected intraperitonially (IP) with NIH:OVCAR-3 human ovarian adenocarcinoma cells. Mice were randomized on day 20 based on CA125 plasma level (i.e. the corresponding biomarker in this example). Human peripheral blood mononuclear cells cells (PBMCs) were injected intravenous (IV) on day 21. Intravenous treatment with pembrolizumab started on day 21 once a week at 10 mg/kg/injection. Tumor development was monitored once a week by measuring CA125 level in mouse blood using ELISA’s analytical assay.

Pembrolizumab treatment was efficient in reducing CA125 level compared to isotype control as observed at day 40.


Legend: Efficacy of a immune checkpoint inhibitor, measurement of circulating biomarker in NIH-OVCAR-3 ovarian carcinoma in PBMC-humanized NOG mouse model


To support your research efforts in oncology and immuno-oncology, our integrated and customized package INPACT PoC Oncology contains all the requirement for a successful preclinical program.

Fix a meeting